SEC Form SC 13G filed by Geron Corporation
$GERN
Biotechnology: Pharmaceutical Preparations
Health Care
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/10/2025 | $1.00 | Sell | Goldman |
| 5/8/2025 | $1.50 | Sector Outperform → Sector Perform | Scotiabank |
| 2/27/2025 | $3.50 → $2.00 | Buy → Neutral | B. Riley Securities |
| 2/26/2025 | Buy → Neutral | H.C. Wainwright | |
| 11/5/2024 | $8.00 | Buy | H.C. Wainwright |
| 10/16/2024 | Sector Outperform | Scotiabank | |
| 9/9/2024 | $7.00 | Outperform | Leerink Partners |
| 4/30/2024 | $4.50 | Outperform → Neutral | Robert W. Baird |
Goldman resumed coverage of Geron with a rating of Sell and set a new price target of $1.00
Scotiabank downgraded Geron from Sector Outperform to Sector Perform and set a new price target of $1.50
B. Riley Securities downgraded Geron from Buy to Neutral and set a new price target of $2.00 from $3.50 previously
Achieved $47.2 million in RYTELO® net product revenue in Q3 2025 Completed enrollment in Phase 3 IMpactMF clinical trial evaluating imetelstat in relapsed/refractory myelofibrosis Strengthened leadership team with appointment of Chief Commercial Officer and additional key executives Announced one oral and four poster presentations accepted at the American Society of Hematology (ASH) 2025 Annual Meeting Company to host conference call and webcast today, November 5, at 8:00 a.m. ET Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today reported financial results for the third quarter of 2025 an
Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that Harout Semerjian, Chief Executive Officer, is scheduled to present at the following investor conferences: Stifel 2025 Healthcare Conference Fireside chat on Tuesday, November 11 at 11:40 AM ET in New York, NY 8th Annual Evercore Healthcare Conference Fireside chat on Tuesday, December 2 at 11:15 AM ET in Miami, FL A live webcast of each fireside chat will be available through the Investors & Media section of Geron's website under Events. A replay of the webcast will be archived on Geron's website. About Geron Geron is
New analysis from the Phase 3 IMerge clinical trial, accepted as an oral presentation, explores relationship between treatment-emergent cytopenias and clinical response in LR-MDS Additional poster presentations include long-term survival outcomes, translational biomarker analyses, and an update on combination therapy trial in myelofibrosis Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that five abstracts – one oral and four poster presentations – have been accepted for presentation at the 67th American Society of Hematology (ASH) 2025 Annual Meeting, to be held December 6-9, 20
For Immediate Release: June 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA announced that it has advised the manufacturers of the licensed and authorized COVID-19 vaccines that the COVID-19 vaccines (2024-2025 Formula) for use in the United States should be monovalent (single strain) JN.1 vaccines to more closely match cu
Submission status for GERON CORP's drug RYTELO (ORIG-1) with active ingredient IMETELSTAT has changed to 'Approval' on 06/06/2024. Application Category: NDA, Application Number: 217779, Application Classification: Type 1 - New Molecular Entity
4 - GERON CORP (0000886744) (Issuer)
3 - GERON CORP (0000886744) (Issuer)
4 - GERON CORP (0000886744) (Issuer)
4 - GERON CORP (0000886744) (Issuer)
4 - GERON CORP (0000886744) (Issuer)
4 - GERON CORP (0000886744) (Issuer)
10-Q - GERON CORP (0000886744) (Filer)
8-K - GERON CORP (0000886744) (Filer)
8-K - GERON CORP (0000886744) (Filer)
SC 13G/A - GERON CORP (0000886744) (Subject)
SC 13G/A - GERON CORP (0000886744) (Subject)
SC 13G - GERON CORP (0000886744) (Subject)
FOSTER CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced several executive transitions and appointments designed to align the company's leadership structure with its strategic priorities. Andrew Grethlein, Ph.D. who joined Geron in September 2012 and has served as Executive Vice President, Chief Operating Officer since January 2019, will depart the company on October 15, 2025, transitioning to a consulting role, while pursuing other interests. Jim Ziegler, who joined the company in September 2024 as Executive Vice President, Chief Commer
ALISO VIEJO, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a privately held ophthalmic biotechnology company, today announced the appointment of Elizabeth (Liz) O'Farrell to its Board of Directors as an Independent Director and Chair of the Audit Committee, effective immediately. Ms. O'Farrell brings over three decades of industry experience, spanning strategic planning, financial optimization, regulatory compliance and management. "Liz's established track record in large, commercial healthcare organizations with deep experience in global finance and operations will be instrumental as we continue to advance our SpyGlass Drug Delivery Platform into two pivotal Phase 3 tria
Industry veteran brings 30+ years of commercial hematology and oncology experience to help accelerate Geron's next phase of growth Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced the appointment of Harout Semerjian as President and Chief Executive Officer (CEO) and a member of the Board of Directors, effective tomorrow. Mr. Semerjian will succeed Dawn Carter Bir, who has served as Interim President and CEO since March 2025. Ms. Bir will continue in her role on Geron's Board of Directors, where she will contribute her insight and strategic counsel. "Our Board conducted an extens
Achieved $47.2 million in RYTELO® net product revenue in Q3 2025 Completed enrollment in Phase 3 IMpactMF clinical trial evaluating imetelstat in relapsed/refractory myelofibrosis Strengthened leadership team with appointment of Chief Commercial Officer and additional key executives Announced one oral and four poster presentations accepted at the American Society of Hematology (ASH) 2025 Annual Meeting Company to host conference call and webcast today, November 5, at 8:00 a.m. ET Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today reported financial results for the third quarter of 2025 an
Geron Corporation (NASDAQ:GERN), a commercial stage biopharmaceutical company aiming to change lives by changing the course of cancer, today announced that it will release its third quarter financial results and business highlights before the market opens on Wednesday, November 5, 2025 via press release, which will be available on the Company's website at www.geron.com/investors. Geron will host a conference call and webcast at 8:00 a.m. Eastern Time. A live webcast of the conference call and related presentation will be available on the Company's website at www.geron.com/investors/events. An archive of the webcast will be available on the Company's website. About Geron Geron is a com
Seasoned Commercial Hematology and Oncology Leader Harout Semerjian Appointed as President and CEO Achieved $49.0 million in RYTELO® net product revenue in Q2 2025 Phase 3 IMpactMF clinical trial in relapsed/refractory myelofibrosis is over 95% enrolled and expected to be fully enrolled by year-end Company to host conference call and webcast today, August 6, at 8:00 a.m. ET Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today reported financial results for the second quarter of 2025 and recent business highlights. In a separate press release today, the Company announced the appointment of H